viewLexagene Hldgs Inc.

LexaGene Holdings reports biggest capital raise to date at C$6.64 million

The biotech issued 12,769,626 units - comprised of a share and a warrant - at a price of C$0.52 per unit

Lexagene Holdings Inc -
The company’s target is to use the proceeds for research, development and marketing as well as bring its genetic analyzer technology to market

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) has succeeded in raising C$6.64 million gross via its latest stock issue – its largest capital raise to date, bringing it closer to its goal of commercialization in 2020.

The company’s target is to use the proceeds for research, development and marketing as well as bring its genetic analyzer technology to market.

The biotechnology company issued 12,769,626 units at C$0.52 per unit, with each unit made up of a share as well as a purchase warrant. The warrant allows for the purchase of a single share at the price of C$0.75 per share until October 29, 2022.

READ: LexaGene is enabling faster, easier pathogen detection

The firm is getting ready to widely launch its LX2 Genetic Analyzer to the veterinary industry and other underserved markets valued at an estimated US$40 billion. The instrument is the first fully-automated pathogen detection platform for use in diagnostics and sample analysis.

Its key feature is its open access nature that allows end users to customize the instrument to target any pathogen of interest. The process is as simple as collecting a sample, loading it into the instrument using a preparation cartridge and pressing “go.” The instrument is able to process multiple samples at a time, returning results within around one hour.

Currently, the main markets being targeted by LexaGene are the vast and underserved veterinary health and food safety industries, but the customizable nature of the technology means that it is applicable to any type of diagnostic industry.

In late morning trade, LexaGene shares slipped 1% to hit C$0.50.

Quick facts: Lexagene Hldgs Inc.

Price: 0.67 CAD

Market: TSX-V
Market Cap: $57.39 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Hldgs Inc. named herein, including the promotion by the Company of Lexagene Hldgs Inc. in any Content on the Site, the Company...



Full interview: Lexagene Develops technology to test for deadly mosquito...

Lexagene (CVE: LXG-OTCQB-LXXGF) Founder and CEO Dr jack Regan joined Steve Darling from Proactive Vancouver on Skype with news the company has used their proprietary technology to develop a detection system for the Eastern Equine Encephalitis or EEE. Regan says that not only can they use the...

on 17/9/19

2 min read